Recently, Dezhou Lanli Biotechnology Co., Ltd. has been granted a national invention patent for its independently developed 'A Soybean Peptide for
Enhancing Immunity and Lowering Blood Pressure, Blood Sugar and Blood Lipids, and a Preparation Method Thereof' (Patent No.: ZL 2024 1 07****85.4,
Publication No.: CN118325998B). This marks another major technological breakthrough for Lanli Biotech in the field of soybean peptides, bringing the
company's proprietary co-fermentation and molecular weight control technologies for plant-derived functional peptides to a new height.
Industry Challenge: Two 'Ceilings' Facing Soybean Peptide

Soybean peptide is a low-molecular-weight peptide mixture derived from soybean protein through enzymatic hydrolysis and microbial fermentation. Thanks
to its high-quality plant protein source and easy absorption, it is widely used in foods, health products and sports nutrition. However, the industry
has long faced two major bottlenecks:
First, single-function products fall short of multi-dimensional needs. Soybean peptides produced by conventional enzymatic hydrolysis tend to have a
relatively high molecular weight and limited peptide activity, making it difficult to deliver stable effects simultaneously in immune support and
metabolic management (blood pressure, blood sugar and blood lipids), thus undermining their functional value.
Second, strain and process bottlenecks restrict large-scale production. In microbial fermentation, a single strain ferments with low efficiency,
resulting in unstable protein content and molecular weight; meanwhile, multi-strain combinations with improper ratios are difficult to synergize in a
sealed fermenter, and the process is complex with a long cycle, which together constrain the industrialized production of high-quality soybean
peptides.
Technological Breakthrough: Five-Strain Co-Fermentation + Membrane Separation Refining
The patent provides a systematic solution from both strain formulation and process design:
1. Synergistic co-fermentation of five probiotics for smaller molecular weight and higher protein content. Lactobacillus acidophilus, Lactobacillus
rhamnosus, Lactobacillus delbrueckii subsp. bulgaricus, Bifidobacterium longum subsp. infantis and Bacillus subtilis are co-fermented at a specific
volume ratio of 2:1:1:1:5 under sealed conditions in a fermenter. Patent experimental data show that with only four strains, the resulting soybean
peptide has a relatively high average molecular weight; only when the five strains are combined at the specific ratio can synergistic enhancement be
achieved, yielding soybean peptide products with smaller molecular weight and higher protein content.
2. Membrane separation + spray drying for a simple process suitable for large-scale production. After preliminary filtration through gauze, the
fermentation broth is filtered a second time through a cellulose membrane with a molecular weight cutoff of 10,000 Da to remove macromolecular
impurities and residual bacterial cells; it is then concentrated under vacuum and spray-dried into powder. The whole process is concise and
time-efficient, making it suitable for industrial-scale application.
Efficacy Verification: Systematic Functional Experiments Disclosed in the Patent Specification
The patent specification discloses systematic efficacy verification experiments:
In terms of immunity: in the mouse experiment on phagocytosis of chicken red blood cells by peritoneal macrophages, the soybean peptide significantly
increased the phagocytic index of immune organs and enhanced mononuclear phagocyte function; in the dinitrofluorobenzene (DNFB)-induced DTH ear
swelling test, the ear weight gain was significantly higher than that of the control group (p<0.05), indicating that the peptide can improve
lymphocyte proliferation and enhance cell-mediated immune function.
In terms of metabolic management: in the mouse lipid-lowering experiment, the soybean peptide exhibited significant regulatory effects on total
cholesterol, triglycerides and low-density lipoprotein, with lipid-lowering efficacy markedly superior to control samples prepared with improper
strain combinations.
It is worth mentioning that the company also holds the invention patent 'A Production Apparatus and Process for Soybean Peptide' (Patent No.: ZL 2023
1 14****85.X, Publication No.: CN117138370B). Together, the two patents form a dual-driven soybean peptide technology system of 'strain fermentation +
equipment and process', achieving full-chain autonomous control from strain formulation and fermentation control to separation and refining.
Lanli Biotech: Building Core Competitiveness in Plant Peptides with Proprietary Patents
Founded in 2017 and located in Linyi Economic Development Zone, Dezhou City, Shandong Province, Dezhou Lanli Biotechnology Co., Ltd. is a high-tech
enterprise dedicated to the research, development, production and sales of bioactive peptides.
The company mainly produces a full range of animal-, plant- and marine-derived bioactive peptides, including fish collagen peptide, bovine collagen
peptide and soybean peptide. It covers an area of approximately 200 mu (about 13.3 hectares), is equipped with 126 specialized large-scale production
facilities, and has an annual production capacity of 19,000 tons.
The company holds 82 proprietary patents in total, including 58 invention patents and 24 utility model patents, and has passed multiple international
certifications such as the ISO9001 quality management system, the HACCP (Hazard Analysis and Critical Control Points) system, and HALAL certification.
Its products have long been exported to Southeast Asia, North America, Australia and other regions.

The recent grant of the invention patent 'A Soybean Peptide for Enhancing Immunity and Lowering Blood Pressure, Blood Sugar and Blood Lipids, and a
Preparation Method Thereof' has further consolidated Lanli Biotech's technological moat in the field of plant-derived functional peptides. Driven by
independent R&D, the company will continue to provide global food, health product and nutrition brands with plant peptide raw material solutions of
higher quality and greater functional value.
---
Dezhou Lanli Biotechnology Co., Ltd.
Service Hotline: 15527430873 | Website: www.lanlicollagen.com | Email: Ziyu@lanlicollagen.com
Contact support